{
"id":"mk19_a_id_s6",
"subspecialtyId":"id",
"title":{
"__html":"<i>Mycobacterium tuberculosis</i> Infection"
},
"jsonContent":{
"type":"section",
"id":"mk19_a_id_s6",
"title":{
"__html":"<i>Mycobacterium tuberculosis</i> Infection"
},
"titleNode":{
"type":"section-title",
"hlId":"35f840",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Mycobacterium tuberculosis"
]
},
" Infection"
]
},
"children":[
{
"type":"section",
"id":"mk19_a_id_s6_1",
"title":{
"__html":"Epidemiology"
},
"titleNode":{
"type":"section-title",
"hlId":"7113ad",
"children":[
"Epidemiology"
]
},
"children":[
{
"type":"p",
"hlId":"8fe114",
"children":[
"Tuberculosis remains one of the most common causes of death from an infectious disease worldwide. Rates of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Mycobacterium tuberculosis"
]
},
" infection remain relatively low in North America. However, approximately one quarter of the world's population is infected with the bacteria. As of 2018, approximately 10 million new ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"M. tuberculosis"
]
},
" infections are reported each year throughout the world, and approximately 1.6 million deaths are documented each year. More than 5000 people per day die of tuberculosis throughout the world. More than 60% of infections are reported from Southeast Asia, India, China, Micronesia, Russia, and sub-Saharan Africa. Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of new infections and 20% of relapsed infections. Extensively drug-resistant tuberculosis (XDR-TB) accounts for approximately 10% of all MDR-TB infections worldwide. In 2018, 9025 tuberculosis infections were reported in the United States (2.8 per 100,000 persons). Infections in the United States occur 15 times more frequently in foreign-born persons than in U.S.-born persons; however, others at high risk include those with alcohol use disorder, urban poor, homeless persons, persons who inject drugs, prison inmates, persons living in shelters, persons with HIV, and older adults."
]
},
{
"type":"p",
"hlId":"cf80c5",
"children":[
"The burden of disease throughout the world and the rate of travel from country to country ensures a steady stream of active tuberculosis cases in the United States."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"797ff4",
"children":[
"Most ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Mycobacterium tuberculosis"
]
},
" infections in the United States occur in foreign-born persons; however, others at high risk include those with alcohol use disorder, urban poor, homeless persons, persons who inject drugs, prison inmates, persons living in shelters, persons with HIV, and older adults."
]
},
{
"type":"keypoint",
"hlId":"4767e4",
"children":[
"Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of new infections and 20% of relapsed infections; extensively drug-resistant tuberculosis accounts for approximately 10% of all MDR-TB infections worldwide."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s6_2",
"title":{
"__html":"Pathophysiology"
},
"titleNode":{
"type":"section-title",
"hlId":"34686e",
"children":[
"Pathophysiology"
]
},
"children":[
{
"type":"p",
"hlId":"c8e164",
"children":[
"Most persons who become infected with ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"M. tuberculosis"
]
},
" remain asymptomatic and develop latent tuberculosis. Specific risk factors for developing active tuberculosis among infected persons are shown in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t18",
"wrapId":"1",
"children":[
"Table 18"
]
}
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_a_id_t18"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"a99bae",
"children":[
"Most persons who become infected with ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Mycobacterium tuberculosis"
]
},
" remain asymptomatic and develop latent tuberculosis."
]
},
{
"type":"keypoint",
"hlId":"a9f5d5",
"children":[
"Risk factors for developing active tuberculosis include recent infection, pulmonary fibrotic lesions, malnutrition, and comorbidities such as immunosuppression, tumor necrosis factor-α inhibitors, injection drug use, silicosis, chronic kidney disease, and diabetes mellitus."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s6_3",
"title":{
"__html":"Clinical Manifestations"
},
"titleNode":{
"type":"section-title",
"hlId":"65ac9d",
"children":[
"Clinical Manifestations"
]
},
"children":[
{
"type":"p",
"hlId":"97d19a",
"children":[
"Tuberculosis is classified as pulmonary, extrapulmonary, or both; the two main forms are primary and secondary tuberculosis. Primary tuberculosis occurs soon after the initial infection, most frequently in children and immunosuppressed persons. Often, the lesions heal spontaneously. Secondary or reactivation tuberculosis results from endogenous reactivation of a latent infection. Most cases of active tuberculosis are caused by reactivation of latent tuberculosis in the setting of immunosuppression. Seventy-five percent of secondary infections are pulmonary, except in those infected with HIV, in whom two thirds of patients have pulmonary and extrapulmonary infection."
]
},
{
"type":"p",
"hlId":"f086ee",
"children":[
"Frequent manifestations of active infection include fever, night sweats, weight loss, productive cough (occasionally blood tinged), anorexia, malaise, and pleuritic chest pain. Hemoptysis occurs in 10% to 20% of patients with positive acid-fast bacilli (AFB) smear results. In immunosuppressed patients, the infection may also spread hematogenously, producing miliary (progressive, widely disseminated) tuberculosis, which can result in a systemic inflammatory response syndrome, septic shock, and ultimately death if not diagnosed and treated early. Additionally, patients with disseminated infection may present with atypical clinical manifestations and chest radiographs. Extrapulmonary disease may be the result of hematogenous dissemination and may be seen in up to 30% of patients with active tuberculosis. It may involve almost any organ system, including the pleura, lymph nodes, central nervous system, skeletal system, pericardium, larynx, peritoneum, and genitourinary system."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"27fd43",
"children":[
"Clinical manifestations of active tuberculosis include fever, night sweats, weight loss, productive cough (occasionally blood tinged), anorexia, malaise, and pleuritic chest pain."
]
},
{
"type":"keypoint",
"hlId":"38a43a",
"children":[
"In immunosuppressed patients, tuberculosis infection may spread hematogenously, resulting in widely disseminated progressive tuberculosis, which can result in a systemic inflammatory response syndrome, septic shock, and ultimately death if not treated early."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s6_4",
"title":{
"__html":"Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"523223",
"children":[
"Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"281b82",
"children":[
"The key to the diagnosis of tuberculosis is a high index of suspicion in patients at high risk."
]
},
{
"type":"section",
"id":"mk19_a_id_s6_4_1",
"title":{
"__html":"Diagnosis of Latent Tuberculosis Infection"
},
"titleNode":{
"type":"section-title",
"hlId":"2731c2",
"children":[
"Diagnosis of Latent Tuberculosis Infection"
]
},
"children":[
{
"type":"p",
"hlId":"4b08f0",
"children":[
"The goal of diagnosing latent tuberculosis infection (LTBI) is to identify and treat persons at increased risk for reactivation tuberculosis. The lifetime risk of developing active infection in patients with LTBI is 5% to 10%, with half of active disease manifesting within 2 years of infection. The risk of developing active tuberculosis is considerably higher in patients who are immunocompromised. The estimated global frequency of LTBI is about 25%. Testing methods include interferon-γ release assay (IGRA) performed on a blood sample or tuberculin skin testing (TST). LTBI is diagnosed when an asymptomatic patient has a positive TST or IGRA result with no clinical or radiographic manifestations of active tuberculosis."
]
},
{
"type":"p",
"hlId":"5ff0c2",
"children":[
"The CDC recommends performing an IGRA rather than a TST in persons 5 years or older who are likely to have ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"M. tuberculosis"
]
},
" infection, have a low or intermediate risk of disease progression, have a history of bacille Calmette-Guérin (BCG) vaccination, or are unlikely to return to have their TST result interpreted. IGRAs are in vitro assays that measure T-cell release of interferon-γ in response to stimulation with highly tuberculosis-specific antigens ESAT-6 and CFP-10 (QuantiFERON-TB Gold In-Tube and T-SPOT.TB test). IGRAs are more specific than TST because they have less cross-reactivity resulting from BCG vaccination and sensitization by nontuberculous mycobacteria. Although not used to diagnose active tuberculosis, IGRAs appear to be at least as sensitive as TST in patients with active tuberculosis."
]
},
{
"type":"p",
"hlId":"010c5d",
"children":[
"TST has become the alternative diagnostic test if IGRA is not feasible or available. The purified protein derivative is injected intradermally and interpreted after 48 to 72 hours by measuring the transverse diameter of induration, not erythema. The criteria for a positive TST result are based on the patient's risk factors for tuberculosis ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t19",
"wrapId":"2",
"children":[
"Table 19"
]
}
]
},
")"
]
},
". A false-negative TST result may occur in patients with recent tuberculosis infection, overwhelming active tuberculosis infection, recent viral infections, or severe immunocompromise (e.g., AIDS) and in those younger than 6 years. Patients with remote exposure to ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"M. tuberculosis"
]
},
" may initially have a negative TST result that can become positive several weeks later after a second TST, known as the “booster effect.” The second test is recommended in health care workers 7 to 21 days after initial testing and should be performed on the opposite forearm; it is not required if IGRA is used. IGRAs are recommended in nearly all clinical settings in which TST is recommended; one exception is children younger than 5 years, for whom experts recommend both tests to increase specificity."
]
},
{
"type":"inline-wrap",
"wrapId":"2",
"contentIds":[
"mk19_a_id_t19"
]
},
{
"type":"p",
"hlId":"60a90a",
"children":[
"Recent guidelines by the CDC do not recommend annual tuberculosis testing for health care personnel unless a known exposure or ongoing transmission is identified in the facility."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"1e5f8a",
"hvc":true,
"children":[
"An interferon-γ release assay is preferred to tuberculin skin testing for ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Mycobacterium tuberculosis"
]
},
" except for those younger than 5 years."
]
},
{
"type":"keypoint",
"hlId":"ee4343",
"children":[
"Latent tuberculosis infection is diagnosed when an asymptomatic patient has a positive tuberculin skin test or interferon-γ release assay result with no clinical or radiographic manifestations of active tuberculosis."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s6_4_2",
"title":{
"__html":"Diagnosis of Active Tuberculosis Infection"
},
"titleNode":{
"type":"section-title",
"hlId":"e48ccb",
"children":[
"Diagnosis of Active Tuberculosis Infection"
]
},
"children":[
{
"type":"p",
"hlId":"a609c5",
"children":[
"The CDC recommends AFB smear microscopy in all patients suspected of having active pulmonary tuberculosis. In vitro fluorescence microscopy of sputum is the preferred methodology. Testing three specimens is highly recommended because false-negative results from a single specimen are not uncommon. However, false-positive results are also not uncommon, thus a positive smear result requires mycobacterial culture confirmation. At least 3 mL of sputum should be submitted, although 5 to 10 mL is preferred. Serial specimens must be obtained at least 8 hours apart, and one must be an early morning specimen. Sputum induction is preferable to bronchoscopy as the sample methodology because of its greater sensitivity in patients who are unable to expectorate sputum."
]
},
{
"type":"p",
"hlId":"ddd51f",
"children":[
"The gold standard for diagnosis of active infection remains the mycobacterial culture. Whether AFB staining results are positive or negative, liquid and solid cultures should be performed for every specimen obtained. Liquid culture allows for faster growth and more rapid identification of organisms (2-4 weeks)."
]
},
{
"type":"p",
"hlId":"047a87",
"children":[
"When a sputum smear result is positive for AFB, nucleic acid amplification testing (NAAT) for ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"M. tuberculosis"
]
},
" is highly recommended to verify the organism. The positive predictive value of a NAAT on a smear-positive sputum sample is 95%. In patients with an intermediate to high level of suspicion for active disease who have a negative smear, the NAAT result will be positive in 65% of persons. If available, a NAAT assay that also detects rifampin resistance is recommended for timely identification. Although the NAAT assays are quick and sensitive, mycobacterial cultures are still recommended so that in vitro susceptibilities can be obtained. A negative NAAT result cannot be used to exclude pulmonary tuberculosis; however, NAAT can confirm the presence of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"M. tuberculosis"
]
},
" in 50% to 80% of AFB smear-negative, culture-positive specimens. Moreover, NAAT can facilitate earlier decision making regarding whether to initiate tuberculosis therapy."
]
},
{
"type":"p",
"hlId":"ec64d1",
"children":[
"If signs of extrapulmonary infection are present, samples from those areas should be obtained and sent for AFB stain, mycobacterial culture, and histopathology. Histopathology may be beneficial by demonstrating caseating granulomas, which are suggestive for but not exclusive to or diagnostic of tuberculosis. In disseminated tuberculosis, blood cultures for mycobacteria using isolator methodology are helpful."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"6f9961",
"children":[
"The gold standard for the diagnosis of active ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Mycobacterium tuberculosis"
]
},
" infection remains the mycobacterial culture; when a sputum smear result is positive for acid-fast bacilli, nucleic acid amplification testing is highly recommended to verify the presence of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"M. tuberculosis"
]
},
"."
]
},
{
"type":"keypoint",
"hlId":"9da9dd",
"children":[
"If signs of extrapulmonary tuberculosis infection are present, samples from those areas should be obtained and sent for acid-fast bacilli staining, mycobacterial culture, and histopathology."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s6_4_3",
"title":{
"__html":"Radiographic Findings"
},
"titleNode":{
"type":"section-title",
"hlId":"38437f",
"children":[
"Radiographic Findings"
]
},
"children":[
{
"type":"p",
"hlId":"05f621",
"children":[
"The classic radiographic finding in pulmonary tuberculosis is that of upper lobe disease with air space disease and cavities ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_a_id_f17",
"wrapId":"3",
"children":[
"Figure 17"
]
}
]
},
")"
]
},
". However, any radiographic pattern can be seen."
]
},
{
"type":"inline-wrap",
"wrapId":"3",
"contentIds":[
"mk19_a_id_f17"
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s6_5",
"title":{
"__html":"Management"
},
"titleNode":{
"type":"section-title",
"hlId":"fe4dbc",
"children":[
"Management"
]
},
"children":[
{
"type":"p",
"hlId":"89281e",
"children":[
"When suitable antimicrobial therapy is administered and taken appropriately, clinical trials demonstrate clinical and microbiologic cure rates of approximately 95%. Therapy depends on several factors, including the classification of infection (latent versus active), pulmonary versus extrapulmonary infection, and patient adherence."
]
},
{
"type":"section",
"id":"mk19_a_id_s6_5_1",
"title":{
"__html":"Treatment of Latent Tuberculosis"
},
"titleNode":{
"type":"section-title",
"hlId":"38dbb1",
"children":[
"Treatment of Latent Tuberculosis"
]
},
"children":[
{
"type":"p",
"hlId":"b07205",
"children":[
"All patients who have a positive IGRA or a positive TST should be evaluated for active disease, with a full medical history, physical examination, and chest radiography, and be screened for HIV infection. If no sign of active infection is present, all patients should be offered treatment for LTBI. The 2020 CDC guidelines include five different treatment regimens ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t20",
"wrapId":"4",
"children":[
"Table 20"
]
}
]
},
")"
]
},
". Pyridoxine is recommended in patients who will receive isoniazid and are at risk for peripheral neuropathy (diabetes mellitus, chronic kidney disease, malnutrition, HIV infection, and alcoholism). Baseline and monthly monitoring of liver chemistry tests are not routinely required unless patients are at risk for hepatotoxicity (HIV, chronic hepatitis B or C infections, alcohol abuse, pregnancy, concurrent hepatotoxic drugs, or underlying liver disease)."
]
},
{
"type":"inline-wrap",
"wrapId":"4",
"contentIds":[
"mk19_a_id_t20"
]
},
{
"type":"p",
"hlId":"1c7984",
"children":[
"In pregnant women with LTBI, a 6- to 9-month regimen of isoniazid plus pyridoxine may be offered; however, some experts prefer to defer therapy until after delivery, unless the patient is at high risk of developing active infection owing to immunocompromise, including HIV infection."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"13727c",
"children":[
"All patients with latent tuberculosis should be screened for HIV infection."
]
},
{
"type":"keypoint",
"hlId":"007084",
"children":[
"Recommended treatment regimens for latent tuberculosis infection include isoniazid plus rifapentine once weekly for 3 months, rifampin daily for 4 months, or isoniazid plus rifampin daily for 3 months."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s6_5_2",
"title":{
"__html":"Treatment of Active Tuberculosis"
},
"titleNode":{
"type":"section-title",
"hlId":"1982f3",
"children":[
"Treatment of Active Tuberculosis"
]
},
"children":[
{
"type":"p",
"hlId":"df21d8",
"children":[
"When active tuberculosis is verified, in vitro susceptibility testing of the initial isolate should be done for the first-line agents (isoniazid, rifampin, pyrazinamide, and ethambutol). This becomes increasingly important because of the advent of MDR and XDR tuberculosis. If rifampin resistance has been detected during NAAT assessment, in vitro susceptibilities to first-line and second-line agents should be performed ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t21",
"wrapId":"5",
"children":[
"Table 21"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"5",
"contentIds":[
"mk19_a_id_t21"
]
},
{
"type":"p",
"hlId":"21590d",
"children":[
"The American Thoracic Society/CDC guidelines published in 2016 recommend 6 to 9 months of treatment in patients with drug-susceptible active tuberculosis. A four-drug regimen is given daily for 2 months, followed by a continuation phase of isoniazid plus rifampin daily, usually for 4 months ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t22",
"wrapId":"6",
"children":[
"Table 22"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"6",
"contentIds":[
"mk19_a_id_t22"
]
},
{
"type":"p",
"hlId":"7a9ce7",
"children":[
"Directly observed therapy, generally through the local health department, must be used when treatment is administered less than 7 days per week. Sputum specimens should be evaluated at 1- and 2-month intervals to assess for efficacy. In addition, clinical assessment and laboratory testing (complete blood count, liver chemistry testing, hepatitis serology) should be performed before initiating therapy."
]
},
{
"type":"p",
"hlId":"fc6977",
"children":[
"It is essential to advise the patient of the possible adverse effect profiles of the various medications (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t21",
"wrapId":"7",
"children":[
"Table 21"
]
}
]
},
")"
]
},
". In several studies, approximately 15% to 25% of patients receiving the four-drug regimen experienced some type of adverse effect. Most adverse effects are mild, and therapy may be continued; up to 15% are severe enough that therapy must be discontinued temporarily. If a hypersensitivity reaction is observed, then all four drugs should be discontinued with sequential rechallenging to determine the cause."
]
},
{
"type":"inline-wrap",
"wrapId":"7",
"contentIds":[
"mk19_a_id_t21"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"798301",
"children":[
"Directly observed therapy is recommended for active tuberculosis treatment regimens when medication is administered less than 7 days per week."
]
},
{
"type":"keypoint",
"hlId":"211315",
"children":[
"American Thoracic Society/CDC guidelines recommend 6 to 9 months of treatment in patients with drug-susceptible active tuberculosis; a four-drug regimen is given daily for 2 months, followed by a continuation phase of isoniazid plus rifampin daily, usually for 4 months."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s6_5_3",
"title":{
"__html":"Drug-Resistant Tuberculosis"
},
"titleNode":{
"type":"section-title",
"hlId":"56c5e4",
"children":[
"Drug-Resistant Tuberculosis"
]
},
"children":[
{
"type":"p",
"hlId":"591a63",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"M. tuberculosis"
]
},
" resistance to individual drugs arises by spontaneous point mutations. Depending on the resistance, the regimen must be altered. In isoniazid-resistant tuberculosis, the recommended regimen of rifampin, ethambutol, and pyrazinamide can be safely administered for 6 months, although adding a later generation fluoroquinolone to the regimen is recommended. In those with isoniazid- and rifampin-resistant tuberculosis (MDR-TB), the recommendation is to use five drugs in the intensive phase of treatment and four drugs in the continuation phase of treatment. The recommended intensive-phase duration is between 5 and 7 months after culture conversion, with the total duration between 15 and 21 months after culture conversion (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t21",
"wrapId":"8",
"children":[
"Table 21"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"8",
"contentIds":[
"mk19_a_id_t21"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"dac620",
"children":[
"In patients with multidrug-resistant tuberculosis (resistant to isoniazid and rifampin), it is recommended to provide a five-drug regimen for 5 to 7 months after culture conversion (intensive-phase of treatment), followed by a four-drug regimen for a total treatment duration of 15 to 21 months after culture conversion (continuation phase)."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s6_5_4",
"title":{
"__html":"Immune Reconstitution Inflammatory Syndrome in Tuberculosis and HIV"
},
"titleNode":{
"type":"section-title",
"hlId":"6f9e42",
"children":[
"Immune Reconstitution Inflammatory Syndrome in Tuberculosis and HIV"
]
},
"children":[
{
"type":"p",
"hlId":"87f1cd",
"children":[
"Tuberculosis in patients with HIV infection may be complicated by immune reconstitution inflammatory syndrome. Although the general recommendations for treatment are the same, antiretroviral therapy should be initiated within 2 weeks for patients with a CD4 cell count less than 50/µL and by 8 to 12 weeks for those with CD4 cell counts of 50/µL or more. An exception is HIV-positive patients with tuberculous meningitis, in whom antiretroviral therapy should not be initiated during the first 8 weeks of tuberculosis therapy regardless of the CD4 cell count to avoid increased morbidity because of immune reconstitution inflammatory syndrome."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"95f1d3",
"children":[
"Tuberculosis in patients with HIV infection may be complicated by immune reconstitution inflammatory syndrome, and antiretroviral therapy initiation should be delayed to prevent this occurrence."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s6_5_5",
"title":{
"__html":"Tumor Necrosis Factor Antagonist and Tuberculosis"
},
"titleNode":{
"type":"section-title",
"hlId":"49bf6b",
"children":[
"Tumor Necrosis Factor Antagonist and Tuberculosis"
]
},
"children":[
{
"type":"p",
"hlId":"b3a6e8",
"children":[
"Patients being treated with a tumor necrosis factor inhibitor (such as infliximab, etanercept, adalimumab, or certolizumab) have been reported to have an increased risk of reactivation tuberculosis and death from disseminated disease. It is recommended that these patients be evaluated for active or latent tuberculosis by performing chest radiography and simultaneous TST or IGRA before beginning this therapy. All patients should receive treatment for tuberculosis (LTBI or active) if identified, although LTBI treatment does not eliminate risk for active mycobacterial infection in this population."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"8c64fe",
"children":[
"Before initiating treatment with tumor necrosis factor inhibitors, all patients should be screened for active or latent tuberculosis; those diagnosed should receive tuberculosis treatment to reduce the risk of reactivation and death from disseminated disease."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s6_6",
"title":{
"__html":"Prevention"
},
"titleNode":{
"type":"section-title",
"hlId":"c53b76",
"children":[
"Prevention"
]
},
"children":[
{
"type":"p",
"hlId":"3facd4",
"children":[
"From the public health perspective, the best way to prevent tuberculosis is to diagnose, isolate, and treat infection rapidly until patients are considered noncontagious and the disease is cured. In hospitalized patients with suspected or documented tuberculosis, airborne precautions should be implemented."
]
},
{
"type":"p",
"hlId":"fe24a4",
"children":[
"CDC guidelines recommend criteria to determine if a patient is no longer contagious and a possible public health threat. These include appropriate antimicrobial therapy for at least 2 weeks, clinical improvement of signs and symptoms, and three negative sputum smears collected at least 8 hours apart, with one being an early-morning specimen. Patients with negative smear results are less contagious, although they may still have tuberculosis."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"d91875",
"children":[
"Guidelines for determining a patient with tuberculosis is no longer contagious include appropriate antimicrobial therapy for at least 2 weeks, clinical improvement in signs and symptoms, and three negative sputum smears collected at least 8 hours apart."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s6_7",
"bibliography":true,
"title":{
"__html":"Bibliography"
},
"titleNode":{
"type":"section-title",
"hlId":"a7cc81",
"children":[
"Bibliography"
]
},
"children":[
{
"type":"references",
"children":[
{
"type":"reference",
"children":[
"Cohen A, Mathiasen VD, Schön T, Wejse C. The global prevalence of latent tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2019 Jun 20. pii: 1900655. doi:10.1183/13993003.00655-2019. [Epub ahead of print] ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31221810",
"target":"_blank"
},
"children":[
"PMID: 31221810"
]
}
]
},
{
"type":"reference",
"children":[
"Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017;64:111-115. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28052967",
"target":"_blank"
},
"children":[
"PMID: 28052967"
]
},
" doi:10.1093/cid/ciw778"
]
},
{
"type":"reference",
"children":[
"Nahid P, Dorman SE, Alipanah N, et al. Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63:853-67. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27621353",
"target":"_blank"
},
"children":[
"PMID: 27621353"
]
},
" doi:10.1093/cid/ciw566"
]
},
{
"type":"reference",
"children":[
"Nahid P, Mase SR, Migliori GB, et al. Treatment of drug-resistant tuberculosis. an official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2019;200:e93-e142. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31729908",
"target":"_blank"
},
"children":[
"PMID: 31729908"
]
},
" doi:10.1164/rccm.201909-1874ST"
]
},
{
"type":"reference",
"children":[
"Otu A, Hashmi M, Mukhtar AM, et al. The critically ill patient with tuberculosis in intensive care: Clinical presentations, management and infection control. J Crit Care. 2018;45:184-196. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29571116",
"target":"_blank"
},
"children":[
"PMID: 29571116"
]
},
" doi:10.1016/j.jcrc.2018.03.015"
]
},
{
"type":"reference",
"children":[
"Sosa LE, Njie GJ, Lobato MN, et al. Tuberculosis screening, testing, and treatment of U.S. health care personnel: recommendations from the National Tuberculosis Controllers Association and CDC, 2019. MMWR Morb Mortal Wkly Rep. 2019;68:439-443. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31099768",
"target":"_blank"
},
"children":[
"PMID: 31099768"
]
},
" doi:10.15585/mmwr.mm6819a3"
]
},
{
"type":"reference",
"children":[
"Stewart RJ, Tsang CA, Pratt RH, et al. Tuberculosis—United States, 2017. MMWR Morb Mortal Wkly Rep. 2018;67:317-323. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29565838",
"target":"_blank"
},
"children":[
"PMID: 29565838"
]
},
" doi:10.15585/mmwr.mm6711a2"
]
}
]
}
]
}
]
},
"tablesContent":{
"mk19_a_id_t18":{
"id":"mk19_a_id_t18",
"number":18,
"bookId":"id",
"title":{
"__html":"Risk Factors for Developing Active <i>Mycobacterium tuberculosis</i>"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"9397a6",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 18. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_id_t18"
}
]
},
"Risk Factors for Developing Active ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Mycobacterium tuberculosis"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"506718",
"class":"cell txt l",
"children":[
"Recent infection (<1 year)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"40443b",
"class":"cell txt l",
"children":[
"Pulmonary fibrotic lesions"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2bf750",
"class":"cell txt l",
"children":[
"Malnutrition"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"228bd0",
"class":"cell txt l",
"children":[
"Comorbidities"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"80a1d1",
"class":"cell txt li",
"children":[
"HIV infection"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"05b10b",
"class":"cell txt li",
"children":[
"Silicosis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0c9768",
"class":"cell txt li",
"children":[
"Chronic kidney disease"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"05159a",
"class":"cell txt li",
"children":[
"Diabetes mellitus"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1ae0e0",
"class":"cell txt li",
"children":[
"Injection drug use"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"782093",
"class":"cell txt li",
"children":[
"Immunosuppressive therapy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a3812b",
"class":"cell txt li",
"children":[
"Jejunoileal bypass"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"21f737",
"class":"cell txt li",
"children":[
"Solid organ transplantation"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"78727f",
"class":"cell txt li",
"children":[
"Tumor necrosis factor-α inhibitors"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5b98f3",
"class":"cell txt li",
"children":[
"Head and neck cancer"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_a_id_t19":{
"id":"mk19_a_id_t19",
"number":19,
"bookId":"id",
"title":{
"__html":"Interpretation of Tuberculin Skin Test Results"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a3c6b8",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 19. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_id_t19"
}
]
},
"Interpretation of Tuberculin Skin Test Results"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"3"
},
"children":[
" ",
{
"type":"p",
"hlId":"08c66a",
"class":"col hd l",
"children":[
"Criteria for Tuberculin Positivity by Risk Group"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f40e44",
"class":"col hd l",
"children":[
"≥5 mm Induration"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6c3dca",
"class":"col hd l",
"children":[
"≥10 mm Induration"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3e36a9",
"class":"col hd l",
"children":[
"≥15 mm Induration"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"330339",
"class":"cell txt l",
"children":[
"HIV-positive persons"
]
},
" ",
{
"type":"p",
"hlId":"48fc28",
"class":"cell txt l",
"children":[
"Recent contacts of persons with active TB"
]
},
" ",
{
"type":"p",
"hlId":"7e9bdb",
"class":"cell txt l",
"children":[
"Persons with fibrotic changes on chest radiograph consistent with old TB"
]
},
" ",
{
"type":"p",
"hlId":"fbb5f5",
"class":"cell txt l",
"children":[
"Patients with organ transplants and other immunosuppressive conditions (receiving the equivalent of ≥15 mg/d of prednisone for >4 weeks)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c65c15",
"class":"cell txt l",
"children":[
"Recent (<5 years) arrivals from high-prevalence countries"
]
},
" ",
{
"type":"p",
"hlId":"e5355b",
"class":"cell txt l",
"children":[
"Persons who inject drugs"
]
},
" ",
{
"type":"p",
"hlId":"a9277b",
"class":"cell txt l",
"children":[
"Residents or employees of high-risk congregate settings: prisons and jails, nursing homes and other long-term facilities for the elderly, hospitals and other health care facilities, residential facilities for patients with AIDS, homeless shelters"
]
},
" ",
{
"type":"p",
"hlId":"7ee9c5",
"class":"cell txt l",
"children":[
"Mycobacteriology laboratory personnel; persons with clinical conditions that put them at high risk for active disease (silicosis, diabetes mellitus, severe kidney disease, certain types of cancer, some intestinal conditions); children aged <4 years or exposed to adults in high-risk categories"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c6383a",
"class":"cell txt l",
"children":[
"All others with no risk factors for TB"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"TB = tuberculosis infection."
]
]
},
"mk19_a_id_t20":{
"id":"mk19_a_id_t20",
"number":20,
"bookId":"id",
"title":{
"__html":"Treatment Regimens for Latent Tuberculosis Infection"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"b910c3",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 20. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_id_t20"
}
]
},
"Treatment Regimens for Latent Tuberculosis Infection"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eac53d",
"class":"col hd l",
"children":[
"Priority Rank",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8aaa9e",
"class":"col hd l",
"children":[
"Regimen"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7cf395",
"class":"col hd l",
"children":[
"Frequency"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e02d2a",
"class":"col hd l",
"children":[
"Duration"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"476f5a",
"class":"col hd l",
"children":[
"Dose",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"672d5b",
"class":"col hd l",
"children":[
"Total Doses"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a054cc",
"class":"cell txt l",
"children":[
"Preferred"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6ba54f",
"class":"cell txt l",
"children":[
"Isoniazid plus rifapentine",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"471d54",
"class":"cell txt l",
"children":[
"Once weekly, directly observed therapy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"de0353",
"class":"cell txt l",
"children":[
"3 months"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d540d0",
"class":"cell txt l",
"children":[
"Isoniazid",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
},
": 15 mg/kg rounded up to the nearest 50 or 100 mg; 900 mg maximum"
]
},
" ",
{
"type":"p",
"hlId":"1d09f4",
"class":"cell txt l",
"children":[
"Rifapentine",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"e"
]
},
":"
]
},
" ",
{
"type":"p",
"hlId":"33a7e9",
"class":"cell txt li",
"children":[
"10.0-14.0 kg: 300 mg"
]
},
" ",
{
"type":"p",
"hlId":"cdbe16",
"class":"cell txt li",
"children":[
"14.1-25.0 kg: 450 mg"
]
},
" ",
{
"type":"p",
"hlId":"69fcd4",
"class":"cell txt li",
"children":[
"25.1-32.0 kg: 600 mg"
]
},
" ",
{
"type":"p",
"hlId":"6f3c45",
"class":"cell txt li",
"children":[
"32.1-49.9 kg: 750 mg"
]
},
" ",
{
"type":"p",
"hlId":"53dba3",
"class":"cell txt li",
"children":[
"≥50.0 kg: 900 mg maximum"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c20ad4",
"class":"cell txt l",
"children":[
"12"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a054cc",
"class":"cell txt l",
"children":[
"Preferred"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7c3720",
"class":"cell txt l",
"children":[
"Rifampin",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"f"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c512b6",
"class":"cell txt l",
"children":[
"Daily"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"790939",
"class":"cell txt l",
"children":[
"4 months"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f0ab17",
"class":"cell txt l",
"children":[
"10 mg/kg"
]
},
" ",
{
"type":"p",
"hlId":"208176",
"class":"cell txt l",
"children":[
"Maximum dose: 600 mg"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"da4fb5",
"class":"cell txt l",
"children":[
"120"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a054cc",
"class":"cell txt l",
"children":[
"Preferred"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0942d2",
"class":"cell txt l",
"children":[
"Isoniazid plus rifampin",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c512b6",
"class":"cell txt l",
"children":[
"Daily"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"de0353",
"class":"cell txt l",
"children":[
"3 months"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dff7ba",
"class":"cell txt l",
"children":[
"Isoniazid",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
},
": 5 mg/kg; 300 mg maximum"
]
},
" ",
{
"type":"p",
"hlId":"3efe32",
"class":"cell txt l",
"children":[
"Rifampin: 10 mg/kg; 600 mg maximum"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"861398",
"class":"cell txt l",
"children":[
"90"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"689609",
"class":"cell txt l",
"children":[
"Alternative",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"g"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6d3bd1",
"class":"cell txt l",
"children":[
"Isoniazid",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c512b6",
"class":"cell txt l",
"children":[
"Daily"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9f7aa8",
"class":"cell txt l",
"children":[
"6 months"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"10e87a",
"class":"cell txt l",
"children":[
"5 mg/kg",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
}
]
},
" ",
{
"type":"p",
"hlId":"b2169a",
"class":"cell txt l",
"children":[
"Maximum dose: 300 mg"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"045117",
"class":"cell txt l",
"children":[
"180"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a84d05",
"class":"cell txt l",
"children":[
"Alternative"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6d3bd1",
"class":"cell txt l",
"children":[
"Isoniazid",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c512b6",
"class":"cell txt l",
"children":[
"Daily"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e195fb",
"class":"cell txt l",
"children":[
"9 months"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"10e87a",
"class":"cell txt l",
"children":[
"5 mg/kg",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
}
]
},
" ",
{
"type":"p",
"hlId":"b2169a",
"class":"cell txt l",
"children":[
"Maximum dose: 300 mg"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"390597",
"class":"cell txt l",
"children":[
"270"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Preferred"
]
},
": excellent tolerability and efficacy; shorter treatment duration; higher completion rates than longer regimens, and therefore higher effectiveness. ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Alternative"
]
},
": excellent efficacy but concerns regarding longer treatment duration; lower completion rates, and therefore lower effectiveness."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Doses listed are for adults."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"Including HIV-positive persons, as drug interactions allow."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
},
"Isoniazid is formulated as 100-mg and 300-mg tablets."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"e"
]
},
"Rifapentine is formulated as 150-mg tablets in blister packs that should be kept sealed until use."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"f"
]
},
"No evidence reported in HIV-positive persons."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"g"
]
},
"Strong recommendation for those persons unable to take a preferred regimen (e.g., because of drug intolerability or drug-drug interactions)."
],
[
"Recommendations from Sterling TR, Njie G, Zenner D, et al. Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep. 2020;69:1-11. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/32053584",
"target":"_blank"
},
"children":[
"PMID: 32053584"
]
},
" doi:10.15585/mmwr.rr6901a1"
]
]
},
"mk19_a_id_t21":{
"id":"mk19_a_id_t21",
"number":21,
"bookId":"id",
"title":{
"__html":"Antituberculous Drugs"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"e6a9d5",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 21. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_id_t21"
}
]
},
"Antituberculous Drugs"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"744605",
"class":"col hd l",
"children":[
"Agent"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b8bc11",
"class":"col hd l",
"children":[
"Adverse Effects"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f4c6f8",
"class":"col hd l",
"children":[
"Notes"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"3"
},
"children":[
" ",
{
"type":"p",
"hlId":"b1ed1f",
"class":"col hd l",
"children":[
"First-Line Medications"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b47e00",
"class":"cell txt l",
"children":[
"Isoniazid"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1fc990",
"class":"cell txt l",
"children":[
"Rash; liver enzyme elevation; hepatitis; peripheral neuropathy; lupus-like syndrome"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4d13ef",
"class":"cell txt l",
"children":[
"Hepatitis risk increases with age and alcohol consumption. Pyridoxine may prevent peripheral neuropathy. Adjust for kidney injury."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6ecbde",
"class":"cell txt l",
"children":[
"Pyrazinamide"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8c1f89",
"class":"cell txt l",
"children":[
"Hepatitis; rash; GI upset; hyperuricemia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"98b4bc",
"class":"cell txt l",
"children":[
"May make glucose control more difficult in patients with diabetes. Adjust for kidney injury."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"335c29",
"class":"cell txt l",
"children":[
"Rifampin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"feef23",
"class":"cell txt l",
"children":[
"Hepatitis; rash; GI upset"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a2ed97",
"class":"cell txt l",
"children":[
"Contraindicated or used with caution when administered with protease inhibitors and nonnucleoside reverse transcriptase inhibitors. Do not administer to patients also taking saquinavir/ritonavir. Colors body fluids orange."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0873c6",
"class":"cell txt l",
"children":[
"Rifabutin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"32c18c",
"class":"cell txt l",
"children":[
"Rash; hepatitis; thrombocytopenia; severe arthralgia; uveitis; leukopenia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e802e3",
"class":"cell txt l",
"children":[
"Dose adjustment required if taken with protease inhibitors or nonnucleoside reverse transcriptase inhibitors. Monitor for decreased antiretroviral activity and for rifabutin toxicity."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cf52fd",
"class":"cell txt l",
"children":[
"Rifapentine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fd9ee6",
"class":"cell txt l",
"children":[
"Similar to rifampin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f06b7b",
"class":"cell txt l",
"children":[
"Contraindicated in patients who are HIV positive (unacceptable rate of failure/relapse)."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"275ecf",
"class":"cell txt l",
"children":[
"Ethambutol"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"29588b",
"class":"cell txt l",
"children":[
"Optic neuritis; rash"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"34dfa1",
"class":"cell txt l",
"children":[
"Baseline and periodic tests of visual acuity and color vision. Patients are advised to call immediately if visual acuity or color vision changes. Adjust for kidney injury."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"3"
},
"children":[
" ",
{
"type":"p",
"hlId":"6b4df9",
"class":"col hd l",
"children":[
"Second-Line Medications",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"593e73",
"class":"cell txt l",
"children":[
"Streptomycin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0f923c",
"class":"cell txt l",
"children":[
"Auditory, vestibular, and kidney toxicity"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bb2e6a",
"class":"cell txt l",
"children":[
"Avoid or reduce dose in adults >59 years. Monitor hearing and kidney function. Adjust dose depending on kidney function."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"23f451",
"class":"cell txt l",
"children":[
"Cycloserine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"423d0a",
"class":"cell txt l",
"children":[
"Psychosis; convulsions; depression; headaches; rash; drug interactions"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2c8170",
"class":"cell txt l",
"children":[
"Pyridoxine may decrease CNS adverse effects. Measure drug serum levels."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e2417a",
"class":"cell txt l",
"children":[
"Capreomycin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"177eb7",
"class":"cell txt l",
"children":[
"Kidney, vestibular, and auditory toxicity"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"693d20",
"class":"cell txt l",
"children":[
"Monitor hearing and kidney function. Adjust dose depending on kidney function."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d8178e",
"class":"cell txt l",
"children":[
"Ethionamide"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"815af4",
"class":"cell txt l",
"children":[
"GI upset; hepatotoxicity; hypersensitivity"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1b27ec",
"class":"cell txt l",
"children":[
"May cause hypothyroidism."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8a0bac",
"class":"cell txt l",
"children":[
"Kanamycin and amikacin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0f923c",
"class":"cell txt l",
"children":[
"Auditory, vestibular, and kidney toxicity"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7f2db7",
"class":"cell txt l",
"children":[
"Not approved by the FDA for TB treatment. Monitor vestibular, hearing, and kidney function."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7960fe",
"class":"cell txt l",
"children":[
"Levofloxacin, moxifloxacin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"83d16f",
"class":"cell txt l",
"children":[
"GI upset; dizziness; hypersensitivity; drug interactions"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa9e6e",
"class":"cell txt l",
"children":[
"Not approved by the FDA for TB treatment. Should not be used in children."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e79937",
"class":"cell txt l",
"children":[
"Para-aminosalicylic acid"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5345a8",
"class":"cell txt l",
"children":[
"GI upset; hypersensitivity; hepatotoxicity"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"631e14",
"class":"cell txt l",
"children":[
"May cause hypothyroidism, especially if used with ethionamide. Measure liver enzyme levels."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1a3cbf",
"class":"cell txt l",
"children":[
"Bedaquiline"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7bab92",
"class":"cell txt l",
"children":[
"Nausea; joint pain; headache; elevated aminotransferase levels; hemoptysis; prolonged QT interval"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4dc048",
"class":"cell txt l",
"children":[
"FDA-approved oral agent for MDR pulmonary TB treatment; indicated for combination therapy when other alternatives are not available. Novel mechanism of action inhibits mycobacterial adenosine triphosphate synthase. Should be given as directly observed therapy."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5e608a",
"class":"cell txt l",
"children":[
"Pretomanid"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a1f726",
"class":"cell txt l",
"children":[
"Peripheral neuropathy; anemia; GI upset; elevated liver enzyme levels; headache; hypoglycemia; rash; hyperamylasemia; visual impairment; diarrhea"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f142be",
"class":"cell txt l",
"children":[
"FDA-approved nitroimidazole, a novel oral agent, for XDR-TB or nonresponsive MDR-TB in combination with bedaquiline and linezolid."
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"CNS = central nervous system; GI = gastrointestinal; MDR = multidrug resistant; TB = tuberculosis; XDR = extensively drug resistant."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Use these drugs in consultation with a clinician experienced in the management of drug-resistant TB."
]
]
},
"mk19_a_id_t22":{
"id":"mk19_a_id_t22",
"number":22,
"bookId":"id",
"title":{
"__html":"Preferred Treatment Regimens for Active Tuberculosis"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"c636e2",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 22. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_id_t22"
}
]
},
"Preferred Treatment Regimens for Active Tuberculosis"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f72f32",
"class":"col hd l",
"children":[
"Treatment Phase"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8aaa9e",
"class":"col hd l",
"children":[
"Regimen"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8413c6",
"class":"col hd l",
"children":[
"Comments"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4f2a91",
"class":"cell txt l",
"children":[
"Initial"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6ac5de",
"class":"cell txt l",
"children":[
"Daily INH, RIF, PZA, and EMB",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
" for 56 doses (8 wk) ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
}
]
},
" ",
{
"type":"p",
"hlId":"223a98",
"class":"cell txt l",
"children":[
"DOT 5 d/wk for 40 doses (8 wk)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0ddada",
"class":"cell txt l",
"children":[
"Alternative regimens available at ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.cdc.gov/tb/topic/treatment/tbdisease.htm",
"target":"_blank"
},
"children":[
"https://www.cdc.gov/tb/topic/treatment/tbdisease.htm"
]
}
]
},
" ",
{
"type":"p",
"hlId":"9c053e",
"class":"cell txt l",
"children":[
"DOT should be used when medications are administered less than 7 d/wk."
]
},
" ",
{
"type":"p",
"hlId":"2e7143",
"class":"cell txt l",
"children":[
"Pyridoxine 25-50 mg/d is given to all patients at risk for neuropathy",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"; 100 mg/d for patients with peripheral neuropathy."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f11580",
"class":"cell txt l",
"children":[
"Continuation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1512d7",
"class":"cell txt l",
"children":[
"INH and RIF 7 d/wk for 126 doses (18 wk) ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
}
]
},
" ",
{
"type":"p",
"hlId":"25d791",
"class":"cell txt l",
"children":[
"DOT 5 d/wk for 90 doses (18 wk)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"661470",
"class":"cell txt l",
"children":[
"Based on expert opinion, patients with cavitation on the initial chest radiograph and positive cultures at completion of 2 months of therapy should receive a 7-month (31-wk) continuation phase."
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"DOT = directly observed therapy; EMB = ethambutol; INH = isoniazid; PZA = pyrazinamide; RIF = rifampin."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"EMB can be discontinued if drug susceptibility studies demonstrate susceptibility to first-line drugs."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Pregnant women; breastfeeding infants; persons with HIV; patients with diabetes, alcoholism, malnutrition, or chronic kidney disease; patients of advanced age."
],
[
"Recommendations from the Centers for Disease Control and Prevention. Tuberculosis. Treatment for TB disease. TB Regimens for Drug-Susceptible TB. Available at ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.cdc.gov/tb/topic/treatment/tbdisease.htm",
"target":"_blank"
},
"children":[
"www.cdc.gov/tb/topic/treatment/tbdisease.htm"
]
},
". Accessed January 26, 2021."
]
]
}
}
}